Literature DB >> 32461575

From NAFLD to MAFLD: when pathophysiology succeeds.

Herbert Tilg1, Maria Effenberger2.   

Abstract

Mesh：

Year:  2020        PMID： 32461575     DOI： 10.1038/s41575-020-0316-6

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  3 in total

Review 1.  A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.

Authors:  Mohammed Eslam; Philip N Newsome; Shiv K Sarin; Quentin M Anstee; Giovanni Targher; Manuel Romero-Gomez; Shira Zelber-Sagi; Vincent Wai-Sun Wong; Jean-François Dufour; Jörn M Schattenberg; Takumi Kawaguchi; Marco Arrese; Luca Valenti; Gamal Shiha; Claudio Tiribelli; Hannele Yki-Järvinen; Jian-Gao Fan; Henning Grønbæk; Yusuf Yilmaz; Helena Cortez-Pinto; Claudia P Oliveira; Pierre Bedossa; Leon A Adams; Ming-Hua Zheng; Yasser Fouad; Wah-Kheong Chan; Nahum Mendez-Sanchez; Sang Hoon Ahn; Laurent Castera; Elisabetta Bugianesi; Vlad Ratziu; Jacob George
Journal:  J Hepatol       Date:  2020-04-08       Impact factor: 25.083

2.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.

Authors:  J Ludwig; T R Viggiano; D B McGill; B J Oh
Journal:  Mayo Clin Proc       Date:  1980-07       Impact factor: 7.616

3.  Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi∗Z Variant of AAT (Pi∗MZ vs Pi∗ZZ genotype) and Noncarriers.

Authors:  Carolin V Schneider; Karim Hamesch; Annika Gross; Mattias Mandorfer; Linda S Moeller; Vitor Pereira; Monica Pons; Pawel Kuca; Matthias C Reichert; Federica Benini; Barbara Burbaum; Jessica Voss; Marla Gutberlet; Vivien Woditsch; Cecilia Lindhauer; Malin Fromme; Julia Kümpers; Lisa Bewersdorf; Benedikt Schaefer; Mohammed Eslam; Robert Bals; Sabina Janciauskiene; Joana Carvão; Daniel Neureiter; Biaohuan Zhou; Katharina Wöran; Heike Bantel; Andreas Geier; Timm Dirrichs; Felix Stickel; Alexander Teumer; Jef Verbeek; Frederik Nevens; Olivier Govaere; Marcin Krawczyk; Tania Roskams; Johannes Haybaeck; Georg Lurje; Joanna Chorostowska-Wynimko; Joan Genesca; Thomas Reiberger; Frank Lammert; Aleksander Krag; Jacob George; Quentin M Anstee; Michael Trauner; Christian Datz; Nadine T Gaisa; Helmut Denk; Christian Trautwein; Elmar Aigner; Pavel Strnad
Journal:  Gastroenterology       Date:  2020-05-04       Impact factor: 22.682
  3 in total
  43 in total

1.  Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH).

Authors:  Giada Sebastiani; Keyur Patel; Vlad Ratziu; Jordan J Feld; Brent A Neuschwander-Tetri; Massimo Pinzani; Salvatore Petta; Annalisa Berzigotti; Peter Metrakos; Naglaa Shoukry; Elizabeth M Brunt; An Tang; Jeremy F Cobbold; Jean-Marie Ekoe; Karen Seto; Peter Ghali; Stéphanie Chevalier; Quentin M Anstee; Heather Watson; Harpreet Bajaj; James Stone; Mark G Swain; Alnoor Ramji
Journal:  Can Liver J       Date:  2022-02-04

2.  Croton urucurana Baill. Ameliorates Metabolic Associated Fatty Liver Disease in Rats.

Authors:  Pablo Alvarez Auth; Gustavo Ratti da Silva; Eduarda Carolina Amaral; Victor Fajardo Bortoli; Mariana Inocencio Manzano; Lauro Mera de Souza; Evellyn Claudia Wietzikoski Lovato; João Tadeu Ribeiro-Paes; Arquimedes Gasparotto Junior; Francislaine Aparecida Dos Reis Lívero
Journal:  Front Pharmacol       Date:  2022-05-20       Impact factor: 5.988

Review 3.  New Avenues for Treatment and Prevention of Drug-Induced Steatosis and Steatohepatitis: Much More Than Antioxidants.

Authors:  Mauro Cataldi; Vincenzo Citro; Chiara Resnati; Federica Manco; Giovanni Tarantino
Journal:  Adv Ther       Date:  2021-03-24       Impact factor: 3.845

Review 4.  Diagnostic management of nonalcoholic fatty liver disease: a transformational period in the development of diagnostic and predictive tools-a narrative review.

Authors:  Natalia Rosso; Adam M Stephenson; Pablo J Giraudi; Claudio Tiribelli
Journal:  Ann Transl Med       Date:  2021-04

5.  Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH.

Authors:  Rebeca Escutia-Gutiérrez; J Samael Rodríguez-Sanabria; C Alejandra Monraz-Méndez; Jesús García-Bañuelos; Arturo Santos-García; Ana Sandoval-Rodríguez; Juan Armendáriz-Borunda
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

6.  Parthenolide plays a protective role in the liver of mice with metabolic dysfunction‑associated fatty liver disease through the activation of the HIPPO pathway.

Authors:  Weihong Wang; Yukai He; Qiuli Liu
Journal:  Mol Med Rep       Date:  2021-05-06       Impact factor: 2.952

Review 7.  Intestinal Barrier and Permeability in Health, Obesity and NAFLD.

Authors:  Piero Portincasa; Leonilde Bonfrate; Mohamad Khalil; Maria De Angelis; Francesco Maria Calabrese; Mauro D'Amato; David Q-H Wang; Agostino Di Ciaula
Journal:  Biomedicines       Date:  2021-12-31

Review 8.  The pathogenic oral-gut-liver axis: new understandings and clinical implications.

Authors:  Jin Imai; Sho Kitamoto; Nobuhiko Kamada
Journal:  Expert Rev Clin Immunol       Date:  2021-06-08       Impact factor: 5.124

9.  Metabolic Dysfunction-associated Fatty Liver Disease is Associated with Greater Impairment of Lung Function than Nonalcoholic Fatty Liver Disease.

Authors:  Lei Miao; Li Yang; Li-Sha Guo; Qiang-Qiang Shi; Teng-Fei Zhou; Yang Chen; Huai Zhang; Hui Cai; Zhi-Wei Xu; Shuan-Ying Yang; Hai Lin; Zhe Cheng; Ming-Yang Zhu; Xu Nan; Shuai Huang; Ya-Wen Zheng; Giovanni Targher; Christopher D Byrne; Yu-Ping Li; Ming-Hua Zheng; Cheng-Shui Chen
Journal:  J Clin Transl Hepatol       Date:  2022-01-04

Review 10.  Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus.

Authors:  Daniel Ferguson; Brian N Finck
Journal:  Nat Rev Endocrinol       Date:  2021-06-15       Impact factor: 43.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.